At the SAPA conference, HanchorBio presented the company’s proprietary Fc-based designer biologics (FBDB™) platform led to biological products that targeting phagocytosis checkpoint blockade and incorporating both innate and adaptive immune responses to treat patients with cancer. During the conference, HanchorBio ended with dozens of one-on-one meetings with national and international partners and multiple possible leads for in-licensing, research collaborations, or commercial right out-licensing conducted by Dr. Yi Du (Sr. Director of Business Development). These discussions mainly focused on advancing science and innovation on the development of anti-tumor immunotherapies to eliminate tumor immune escape.

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.